Media Articles Related to Priftin (Rifapentine)
Is Tuberculosis (TB) Contagious?
Source: MedicineNet Chronic Cough Specialty [2016.08.16]
Title: Is Tuberculosis (TB) Contagious?
Category: Diseases and Conditions
Created: 8/24/2015 12:00:00 AM
Last Editorial Review: 8/16/2016 12:00:00 AM
HIV is not a super-spreader of drug-resistant tuberculosis
Source: HIV / AIDS News From Medical News Today [2016.08.11]
While the human immunodeficiency virus (HIV) pandemic fuels tuberculosis (TB) outbreaks, it does not drive the development and transmission of multidrug-resistance in TB patients as previously...
Mass imprisonment of drug users driving global epidemics of HIV, hepatitis, and tuberculosis
Source: HIV / AIDS News From Medical News Today [2016.07.15]
The War on Drugs, mass incarceration of drug users, and the failure to provide proven harm reduction and treatment strategies has led to high levels of HIV, tuberculosis, and hepatitis B and C...
Source: MedicineNet Amyloidosis Specialty [2016.06.02]
Title: Tuberculosis (TB)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/2/2016 12:00:00 AM
Statins cut tuberculosis treatment time in mice
Source: Statins News From Medical News Today [2016.03.17]
In a study using mice, the Johns Hopkins University School of Medicine infectious disease experts have added to evidence that statin drugs -- known primarily for their cholesterol-lowering effects...
Published Studies Related to Priftin (Rifapentine)
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. [2006.04.15]
RATIONALE: Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies. OBJECTIVES: To compare the efficacy of weekly rifapentine/isoniazid to daily rifampin/pyrazinamide in preventing TB in household contacts of patients with pulmonary TB in Brazil... CONCLUSIONS: Rifapentine/isoniazid was better tolerated than rifampin/pyrazinamide and was associated with good protection against TB. Rifapentine/isoniazid weekly for 12 wk is likely a promising therapy for latent TB infection.
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. [2004.06.01]
The pharmacokinetics of rifapentine at 600, 900, and 1,200 mg were studied during once-weekly continuation phase therapy in 35 patients with tuberculosis. Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression).
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. [2003.05.15]
To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial...
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. [2002.06.01]
Once-weekly rifapentine 600 mg plus isoniazid (INH) during the continuation phase treatment of tuberculosis is associated with a relapse rate higher than that of twice-weekly rifampin plus INH... Further evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted.
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. [2002.01]
SETTING: Clinical trial in 672 patients with newly diagnosed pulmonary tuberculosis in Hong Kong. After an initial 2 months of a four-drug intensive phase consisting of thrice-weekly streptomycin, isoniazid, rifampicin and pyrazinamide (SHRZ), a random allocation was made to a continuation phase of once-weekly 600 mg rifapentine + 15 mg/kg isoniazid (HRp1), HRp1 given in 2 of every 3 weeks (HRp1.2/3), or to thrice-weekly isoniazid + rifampicin (HR3), the standard treatment in Hong Kong. OBJECTIVE: Final report evaluating adverse events (46 relapses and one failure) after 5 years and the prognostic influence of various factors... CONCLUSIONS: The two rifapentine regimens were unsatisfactory because of their high incidence of adverse events. Isoniazid appeared not to contribute to preventing relapse. Further studies with increased rifapentine dosage are necessary.
Clinical Trials Related to Priftin (Rifapentine)
Study of Daily Rifapentine for Pulmonary Tuberculosis [Completed]
The goal of this Phase 2 study is to determine the microbiological activity and safety of
rifapentine when given as a component of multidrug intensive phase treatment of
smear-positive pulmonary TB.
Funding Source- FDA OOPD
High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis [Completed]
The primary objective of this study is to characterize rifapentine drug levels in patients
with TB in relationship to its effectiveness in treating TB and any adverse effects
experienced by participants.
The Effect of Rifapentine on Raltegravir [Completed]
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment [Completed]
Protocol Synopsis The goal of this Phase 2 clinical trial is to evaluate the antimicrobial
activity and safety of an experimental intensive phase (first 8 weeks of treatment)
tuberculosis treatment regimen in which rifapentine is substituted for rifampin.
- To compare the antimicrobial activity and safety of standard daily regimen comprised of
rifampin (approximately 10 mg/kg/dose) + isoniazid + pyrazinamide + ethambutol (RHZE)
to that of an experimental regimen comprised of rifapentine (approximately 10
mg/kg/dose) + isoniazid + pyrazinamide + ethambutol (PHZE).
- To determine and compare for each regimen the time to culture-conversion, using data
from 2-, 4-, 6-, and 8-week cultures (10, 20, 30, 40 doses).
- To determine and compare for each regimen the proportion of patients with any Grade 3
or 4 adverse reactions
- To determine the correlation of the MGIT/BACTEC liquid culture growth index and other
mycobacterial and clinical biomarkers with time to culture conversion and treatment
- To store serum for future assessment of biomarkers of TB treatment response and
hypersensitivity to study drugs.
- To compare adverse events and 2-month culture conversion rates among HIV-infected
patients vs. HIV-uninfected patients
- To determine the tolerability and safety, and estimate the antimicrobial activity, of
experimental regimens that include isoniazid + pyrazinamide + ethambutol plus either
rifapentine 15 mg/kg/dose or rifapentine 20 mg/kg/dose, all administered daily.
Assessment of these doses of rifapentine will be performed as an extension to the main
study after enrollment in the main study has been completed.
This will be a prospective, multicenter, open-label clinical study. Adults suspected of
having pulmonary tuberculosis who meet eligibility criteria will be randomized to receive
either the experimental intensive phase tuberculosis treatment regimen or the standard
intensive phase tuberculosis treatment regimen. Randomization will be stratified by
presence/absence of cavitation on baseline chest radiograph, and by geographic continent.
All doses of study drugs will be given under direct observation and administered 5 days per
week. After a subject completes intensive phase therapy, he/she then will be treated with a
non-experimental continuation phase tuberculosis treatment regimen.
The study extension will be a prospective, multicenter clinical trial. Eligibility criteria
will be the same as for the main study. Participants will be randomized to one of four
regimens: the standard intensive phase treatment regimen, an investigational regimen in
which rifapentine 10 mg/kg/dose is substituted for rifampin, an investigational regimen in
which rifapentine 15 mg/kg/dose is substituted for rifampin, or an investigational regimen
in which rifapentine 20 mg/kg is substituted for rifampin. Randomization will be stratified
by the presence/absence of cavitation on baseline chest radiograph, and by study site. Study
drugs will be administered 7 days per week. After a subject completes intensive phase
therapy, he/she then will be treated with a non-experimental continuation phase tuberculosis
treatment regimen. Subjects will have blood drawn for one pharmacokinetic determination of
rifapentine concentration at or after the week 2 visit during intensive phase therapy.
This study is being conducted in 2 phases.
1. The main study compares a 10 mg/kg dose of rifapentine, open label, against 10 mg/kg
rifampin in an otherwise standard intensive phase regimen of treatment for pulmonary
tuberculosis. The projected sample size was 480 enrollments; 530 patients were
2. The study extension evaluates higher doses of rifapentine, with the specific
rifapentine doses (10 mg/kg, 15 mg/kg, and 20 mg/kg) blinded to patients and
clinicians, with data collection and endpoints otherwise similar to the main study.
The projected sample size for the study extension is 320 enrollments.
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens [Not yet recruiting]
The purpose of this study is to determine whether one or two four-month regimens of
tuberculosis treatment are as effective as a standard six-month regimen for treatment of
pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each
week, with direct observation of each dose by a health-care worker at least five of the
seven days of each week.
The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and
pyrazinamide followed by four months of isoniazid and rifampin.
The first short regimen is a single substitution of rifapentine for rifampin: two months of
isoniazid, rifapentine, ethambutol, and pyrazinamide, followed by two months of isoniazid
The second short regimen is a double substitution of rifapentine for rifampin and
moxifloxacin for ethambutol: two months of isoniazid, rifapentine, moxifloxacin, and
pyrazinamide, followed by two months of isoniazid, rifapentine, and moxifloxacin.
Target enrollment is 2500 participants. Each study participant will remain in the study for
18 months in order to include at least 12 months of evaluation of whether the participant's